Why did ALNFL.PA stock jump today?

ALNFL.PA stock rose **15.60%** intraday on heavy volume (**251,123** shares). The move likely reflects renewed interest in its Phase III pipeline and concentrated trading rather than an earnings update.

What is Meyka AI’s view on ALNFL.PA stock?

Meyka AI gives ALNFL.PA a **C+ (58.61/100)** grade with a HOLD suggestion. The grade weighs sector performance, financial growth, and key metrics. This is informational, not investment advice.

How does the Meyka AI forecast compare to the current price?

Meyka AI's yearly forecast is **€0.80**, below the current **€1.63**, implying **-50.92%** to that model target. Monthly forecast is **€1.32**, implying **-18.40%** versus the current price.

What are the main risks for ALNFL.PA stock?

Main risks include negative earnings (EPS **-€0.28**), expensive PB (**10.02**), small market cap (**€18.25m**), and binary clinical trial outcomes that can cause sharp moves.

EU Stocks

ALNFL.PA +15.60% intraday 21 Jan 2026 (NFL Biosciences, EURONEXT): heavy volume may signal catalyst

ByHuzaifa Zahoor January 21, 2026January 21, 2026

ALNFL.PA stock led intraday movers on 21 Jan 2026 after a 15.60% rise to €1.63 on EURONEXT. Volume hit 251,123 shares, about 3.97x the 50,000+ average, signalling unusual investor attention. The move coincides with the company’s Phase III pipeline focus and tighter technical indicators. We examine drivers, valuation, Meyka AI grade, and a short-term forecast to help traders assess risk and opportunity.